A significant upregulation of ALDH1A1 protein, which is associated with cancer stemness and metastatic potential 46, was also observed in the CML-treated group compared to the control group (Figure 3C, 3G). The gene discussed is ALDH1A1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.